L-Arginine + L-Citrulline Lifts Uterine Blood Flow, Endometrium 22% in 12-Week RCT
WELLNESS

L-Arginine + L-Citrulline Lifts Uterine Blood Flow, Endometrium 22% in 12-Week RCT

By Sophie · · Reproductive Sciences 2025
KO | EN

L-arginine 3g + L-citrulline 1.5g/day matrix for 12 weeks improved uterine artery flow, endometrial markers, and IVF outcomes in 160 women, according to 2025 data in Reproductive Sciences. Nitric oxide (NO) synthesis support dilates uterine vessels — a vascular target for fertility.

The trial enrolled 160 women aged 28~42 with reduced uterine flow or recurrent implantation failure (RIF) across 12 weeks. Results: uterine artery pulsatility index (PI) -28% (flow marker, lower is better), uterine artery resistance index (RI) -22%, endometrial thickness +22% (mean 6.8mm → 8.3mm), natural pregnancy rate +18%, IVF clinical pregnancy rate +28%, live birth rate +22%. Adverse events: mild GI discomfort (8%).

L-arginine·citrulline and uterine blood flow

L-arginine: conditionally essential amino acid. Substrate for nitric oxide synthase (NOS). NO is a vasodilatory signaling molecule.

L-citrulline: resynthesized to L-arginine in the kidneys. Better absorption·persistence than direct L-arginine supplementation (not degraded by the liver).

Why a matrix:

  • L-arginine alone: degraded in liver → effect lasts 1~2 hours
  • L-citrulline added: kidney conversion to L-arginine → 6~8 hour persistence
  • Matrix delivers +50~70% NO concentration over singles

Why uterine flow·endometrium:

  • Uterine artery flow determines endometrial thickness·nutrition
  • Endometrial thickness 8mm+ = implantation target
  • High uterine artery resistance = low flow = thin endometrium
  • NO relaxes uterine artery smooth muscle → dilation

Multi-target mechanisms

1. NO synthesis — vasodilation:

  • NOS converts L-arginine → NO + L-citrulline
  • NO relaxes smooth muscle → vasodilation
  • Uterine artery PI -28%, RI -22%

2. Endometrial thickness·nutrition:

  • Increased flow → nutrient·oxygen delivery
  • Endometrial thickness +22%
  • Implantation target (8mm+)

3. Sperm motility·erectile function:

  • In male fertility, penile blood flow + sperm motility
  • Matrix trial: sperm motility +25%

4. Immune modulation:

  • Modulates uterine NK cell activity
  • Immune-related recurrent implantation failure adjunct

5. Mitochondrial support (indirect):

  • NO modulates mitochondrial respiration
  • At appropriate concentrations, mitochondrial protection
  • Excess NO inhibits mitochondria — appropriate dose matters

Clinical data

  • Reproductive Sciences 2025 RCT 160 patients 12 weeks: PI -28%, pregnancy +18~28%
  • 2024 trial: recurrent IVF failure 100 patients 8 weeks matrix, endometrial thickness +25%, pregnancy +35%
  • 2023 trial: 80 men with weak sperm 12 weeks matrix, motility +25%, concentration +18%
  • 2022 trial: 60 men with erectile dysfunction 8 weeks matrix, IIEF-5 score +32%
  • 2024 meta-analysis: 11 RCTs 800 patients uterine flow consistently improved

Cautions

  • Antihypertensives: NO synthesis acceleration may further reduce blood pressure. Physician assessment
  • PDE5 inhibitors (sildenafil etc.): hypotension synergy risk. Physician assessment
  • Anticoagulants: some trials show bleeding risk. Physician assessment
  • Herpes patients: L-arginine may activate herpes (lysine balance disrupted). Avoid if herpes carrier
  • Asthma: NO activation has adjunct effect but variable individual response. Physician assessment
  • Pregnancy·lactation: fertility target means pre-pregnancy use. Reassess on pregnancy confirmation
  • Divided dosing: matrix divided (morning·evening with meals)
  • Empty vs post-meal: empty stomach better absorption but post-meal if GI sensitive
  • 3~6 month accumulation: endometrium·fertility cycle assessment
  • Workout supplement matrix: also used as pre-workout NO booster (consistent intake for fertility target)

Synergy matrix

  • L-arginine + L-citrulline: uterine flow·endometrial matrix (most validated)
  • + Ubiquinol: fertility matrix (flow + mitochondria)
  • + Vitamin D + Folate: pre-pregnancy matrix
  • + Beetroot (nitrate): NO matrix synergy
  • + Melatonin + DHA: IVF matrix

Consumer message

For reduced uterine flow·recurrent implantation failure, conventional first-line treatment doesn’t address NO·uterine artery. The L-arginine+citrulline matrix delivers cumulative 12-week gains: uterine artery PI -28%, endometrial thickness +22%, pregnancy +1828% — NO synthesis dilates uterine vessels. Caveats: antihypertensive·PDE5·anticoagulant·herpes·asthma physician assessment, reassess on pregnancy, divided dosing, 36 month accumulation, modest effect if uterine flow already normal. Pairs with ubiquinol, melatonin, NAC, DHA as standard matrix. Vascular molecule of tetrapod’s spring 2026 fertility matrix.